Results 61 to 70 of about 618,864 (305)

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Modulation of Immunity by Lymphatic Dysfunction in Lymphedema

Frontiers in Immunology, 2019
The debilitating condition known as secondary lymphedema frequently occurs after lymphadenectomy and/or radiotherapy for the treatment of cancer. These therapies can damage lymphatic vessels leading to edema, fibrosis, inflammation and dysregulated ...
Yinan Yuan, Valeria Arcucci, Sidney M. Levy, Marc G. Achen, Marc G. Achen   +4 more
doaj   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Cross talk Initiated by Endothelial Cells Enhances Migration and Inhibits Anoikis of Squamous Cell Carcinoma Cells through STAT3/Akt/ERK Signaling

Neoplasia: An International Journal for Oncology Research, 2009
It is well known that cancer cells secrete angiogenic factors to recruit and sustain tumor vascular networks. However, little is known about the effect of endothelial cell-secreted factors on the phenotype and behavior of tumor cells.
Kathleen G. Neiva, Zhaocheng Zhang, Marta Miyazawa, Kristy A. Warner, Elisabeta Karl, Jacques E. Nör   +5 more
doaj   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo [PDF]

, 2007
Endothelial cell survival is indispensable to maintain endothelial integrity and initiate new vessel formation. We investigated the role of SHP-2 in endothelial cell survival and angiogenesis in vitro as well as in vivo.
Groesser, Leopold, Walzog, Barbara, Gloe, Torsten, Sohn, Hae-Young, Krötz, Florian, Plank, Christian, Pohl, Ulrich, Hellwig, Nicole, Mannell, Hanna, Mannell, Hanna;Hellwig, Nicole;Gloe, Torsten;Plank, Christian;Sohn, Hae-Young;Groesser, Leopold;Walzog, Barbara;Pohl, Ulrich;Krötz, Florian, Mannell, H;Hellwig, N;Gloe, T;Plank, C;Sohn, HY;Groesser, L;Walzog, B;Pohl, U;Krötz, F   +10 more
core   +1 more source

Anti-tumor efficacy and Vδ2 T-cell activation via EGFR antibody-drug conjugates featuring novel aminobisphosphonates

Scientific Reports
Antibody–drug conjugates (ADCs) represent a promising strategy in cancer therapy, enabling the targeted delivery of cytotoxic agents to tumor cells. In this study, we developed and characterized novel ADCs combining the anti-EGFR monoclonal therapeutic ...
Doretta Cuffaro, Linda Di Gregorio, Camilla Mangini, Martina Taglieri, Serena Matis, Roberto Benelli, Massimo Ardy, Laura Salvini, Armando Rossello, Alessandro Poggi, Lizzia Raffaghello, Elisa Nuti   +11 more
doaj   +1 more source

Atorvastatin Promotes Phagocytosis and Attenuates Pro-Inflammatory Response in Human Retinal Pigment Epithelial Cells

Scientific Reports, 2017
Phagocytosis of daily shed photoreceptor outer segments is an important function of the retinal pigment epithelium (RPE) and it is essential for retinal homeostasis.
Bo Tian, Ahmad Al-Moujahed, Peggy Bouzika, Yijun Hu, Shoji Notomi, Pavlina Tsoka, Joan W. Miller, Haijiang Lin, Demetrios G. Vavvas   +8 more
doaj   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Angiogenesis and obesity [PDF]

Cardiovascular Research, 2008
Development of obesity is associated with substantial modulation of adipose tissue structure, involving adipogenesis, angiogenesis, and extracellular matrix remodelling. These processes require proteolytic activity, provided mainly by the fibrinolytic (plasminogen/plasmin), matrix metalloproteinase, and ADAM/ADAMTS systems.
openaire   +2 more sources